PLUVICTO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
PLUVICTO
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
lutetium (177Lu) vipivotide tetraxetan
Registration type
NCE/ NBE
Indication
PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.